Meek's bold M&A plan paying off for Ipsen

26 April 2018

French drugmaker Ipsen (Euronext: IPN) has reported first quarter revenues of 510 million euros ($620 million), up from 438 million euros in first-quarter 2017, just shy of most analysts’ expectations.

The bulk of the growth came from the firm's specialty care division, which took in 440 million euros, up from 366 million euros last year. Shares were buoyant in morning trading, up nearly 3% from the prior day’s close.

Following international financial reporting standards, the sales growth of 16.5% was hit by the strong performance of the euro against a number of currencies, notably the US dollar.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK